Investor Presentaiton
Major R&D Milestones (Alpha)
DS-7300
Project
Quizartinib
Valemetostat
(DS-3201)
DS-9606
•
.
•
Target Indication [phase, study name]
•
ES-SCLC, 2L [P2, JP/US/EU/Asia]
AML, 1L [P3, JP/US/EU/Asia]
ATL/L [Registrational P2, JP]
Solid tumors [P1, US/EU]
•
.
H1
FY2022
Study started
Filing anticipated
(JP/US/EU)
• Approval anticipated
(JP)
⚫ Study started
DS-2325
•
Netherton syndrome [P1, US]
DS-5670
•
COVID-19 mRNA vaccine, booster [P1/2/3, JP]
.
• Study started
H2
12
•
TLR anticipated
As of Jul 2022
Daiichi-Sankyo
• Filing anticipated (JP)
Bold: update from FY2021 Q4
AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, ES-SCLC: extensive stage-small cell lung cancer, TLR: top line results
The timeline indicated is based on the current forecast and subject to change.
FY2023
• Approval
anticipated
(JP/US/EU)
40View entire presentation